Literature DB >> 27689453

Concomitant Medication Use and New-Onset Diabetes Among Medicaid Beneficiaries with Chronic Obstructive Pulmonary Disease.

Mayank Ajmera1, Chan Shen2, Usha Sambamoorthi3.   

Abstract

Use of multiple prescription medications is common among individuals with chronic obstructive pulmonary disease (COPD) because of coexisting inflammatory-related conditions. Specifically, the use of antidepressants, inhaled corticosteroids (ICSs), and statins may place individuals with COPD at high risk for new-onset diabetes. The objective was to examine the relationship between the use of antidepressants, ICSs, and statins and new-onset diabetes among Medicaid beneficiaries with COPD. This study used a retrospective longitudinal cohort design using multiple years (2005-2008) of Medicaid claims for beneficiaries with newly diagnosed COPD (n = 15,287), who were diabetes free at baseline. National Drug Codes were used to determine the receipt of antidepressants, ICSs, and statins, and International Classification of Diseases, Ninth Revision, Clinical Modification codes were used to define new-onset diabetes (250.x2). Multivariable logistic regression was used to examine the adjusted relationship between medication use and new-onset diabetes. Overall, 6.3% of the study population was diagnosed with new-onset diabetes. After controlling for baseline characteristics, individuals using ICSs (adjusted odds ratio [AOR]: 1.23; 95% confidence interval [CI]: 1.07, 1.47) or statins (AOR: 1.48; 95% CI: 1.27, 1.72) had a greater risk of new-onset diabetes compared to those not given ICSs, statins, or antidepressants. Analyses using combined medication categories revealed that adults using statins in combination with both antidepressants and ICSs, or when combined with ICS, were more likely to have new-onset diabetes. These findings indicate that multiple medication use (ICSs and statins) was associated with increased rates of new-onset diabetes. Further research is warranted to understand this association.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27689453      PMCID: PMC5749606          DOI: 10.1089/pop.2016.0047

Source DB:  PubMed          Journal:  Popul Health Manag        ISSN: 1942-7891            Impact factor:   2.459


  33 in total

1.  From COPD to chronic systemic inflammatory syndrome?

Authors:  Leonardo M Fabbri; Klaus F Rabe
Journal:  Lancet       Date:  2007-09-01       Impact factor: 79.321

2.  Use of antidepressants and statins and short-term risk of new-onset diabetes among high risk adults.

Authors:  Rituparna Bhattacharya; Mayank Ajmera; Sandipan Bhattacharjee; Usha Sambamoorthi
Journal:  Diabetes Res Clin Pract       Date:  2014-06-04       Impact factor: 5.602

3.  Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

Authors:  David Preiss; Sreenivasa Rao Kondapally Seshasai; Paul Welsh; Sabina A Murphy; Jennifer E Ho; David D Waters; David A DeMicco; Philip Barter; Christopher P Cannon; Marc S Sabatine; Eugene Braunwald; John J P Kastelein; James A de Lemos; Michael A Blazing; Terje R Pedersen; Matti J Tikkanen; Naveed Sattar; Kausik K Ray
Journal:  JAMA       Date:  2011-06-22       Impact factor: 56.272

Review 4.  Using administrative data to study persons with disabilities.

Authors:  Lisa I Iezzoni
Journal:  Milbank Q       Date:  2002       Impact factor: 4.911

Review 5.  Administrative and claims records as sources of health care cost data.

Authors:  Gerald F Riley
Journal:  Med Care       Date:  2009-07       Impact factor: 2.983

6.  Identifying individuals with physcian diagnosed COPD in health administrative databases.

Authors:  A S Gershon; C Wang; J Guan; J Vasilevska-Ristovska; L Cicutto; T To
Journal:  COPD       Date:  2009-10       Impact factor: 2.409

7.  Impaired basal glucose effectiveness but unaltered fasting glucose release and gluconeogenesis during short-term hypercortisolemia in healthy subjects.

Authors:  Michael F Nielsen; Andrea Caumo; Visvanathan Chandramouli; William C Schumann; Claudio Cobelli; Bernard R Landau; Hendrik Vilstrup; Robert A Rizza; Ole Schmitz
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-09-09       Impact factor: 4.310

Review 8.  Antidepressant use and new-onset diabetes: a systematic review and meta-analysis.

Authors:  Sandipan Bhattacharjee; Rituparna Bhattacharya; George A Kelley; Usha Sambamoorthi
Journal:  Diabetes Metab Res Rev       Date:  2013-05       Impact factor: 4.876

9.  The validity of using ICD-9 codes and pharmacy records to identify patients with chronic obstructive pulmonary disease.

Authors:  Colin R Cooke; Min J Joo; Stephen M Anderson; Todd A Lee; Edmunds M Udris; Eric Johnson; David H Au
Journal:  BMC Health Serv Res       Date:  2011-02-16       Impact factor: 2.655

10.  Explaining the increased health care expenditures associated with gastroesophageal reflux disease among elderly Medicare beneficiaries with chronic obstructive pulmonary disease: a cost-decomposition analysis.

Authors:  Mayank Ajmera; Amit D Raval; Chan Shen; Usha Sambamoorthi
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-04-08
View more
  3 in total

1.  Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population.

Authors:  Theodore K Marras; Christopher Vinnard; Quanwu Zhang; Keith Hamilton; Jennifer Adjemian; Gina Eagle; Raymond Zhang; Engels Chou; Kenneth N Olivier
Journal:  Respir Med       Date:  2018-10-22       Impact factor: 3.415

2.  Prevalence of Asthma Characteristics in COPD Patients in a Dutch Well-Established Asthma/COPD Service for Primary Care.

Authors:  Anna Jetske Baron; Bertine M J Flokstra-de Blok; Ellen van Heijst; Roland A Riemersma; Agnes M M Sonnenschein-van der Voort; Esther I Metting; Janwillem W H Kocks
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-07-06

3.  Chronic obstructive pulmonary disease, lung function and risk of type 2 diabetes: a systematic review and meta-analysis of cohort studies.

Authors:  Yang Peng; Guo-Chao Zhong; Lingxiao Wang; Lijuan Guan; Ao Wang; Kai Hu; Jing Shen
Journal:  BMC Pulm Med       Date:  2020-05-11       Impact factor: 3.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.